纳米医学的进步,用于精确的胰岛素输送
Alfredo Caturano1,2, Roberto Nilo3, Davide Nilo1
1Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, 80138 Naples, Italy.
Pharmaceuticals (Basel, Switzerland)
|July 27, 2024
概括
纳米医学为糖尿病提供先进的胰岛素输送,通过克服传统注射限制,提高治疗效率和患者安全. 未来的纳米载体的目标是精确的准和糖尿病管理中的实时监控.
科学领域:
- 生物医学工程 生物医学工程
- 材料科学 材料科学 材料科学
- 内分泌学 在内分泌学.
背景情况:
- 糖尿病是一种日益严重的全球健康问题,其特点是高血糖.
- 胰岛素治疗至关重要,特别是1型糖尿病,但注射等传统方法存在局限性.
- 纳米医学为增强胰岛素输送提供了创新解决方案,解决了稳定性差和患者合规性等挑战.
研究的目的:
- 审查纳米医学在糖尿病管理中的胰岛素输送中的当前应用.
- 检查各种纳米载体系统及其作用机制.
- 讨论基于纳米医学的糖尿病治疗的挑战和未来前景.
主要方法:
- 关于用于输送胰岛素的纳米药物的当前文献的综述.
- 分析不同类型的纳米载体 (脂质体,酸盐,PLGA) 和它们的特性.
- 讨论基于纳米技术的产品的安全考虑和监管指导.
主要成果:
- 纳米载体保护胰岛素免受降解,改善稳定性,并使其可控释放.
- 纳米医学增强了胰岛素的生物可用性,持续释放和向能力.
- 新兴的纳米医学方法显示出改善糖尿病管理和患者结果的希望.
结论:
- 纳米医学具有巨大的潜力,可以克服传统胰岛素输送方法的局限性.
- 需要进一步的研究和开发来解决安全问题,并优化纳米载体设计用于糖尿病治疗.
- 未来的纳米医药战略将专注于针对性,响应性和监控性胰岛素输送系统,以改善糖尿病护理.
相关概念视频
Insulin Formulations: Types and Delivery
181
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
181
Insulin: Biosynthesis, Chemistry, and Preparation
366
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
366
Insulin: Dosing Regimen and Adverse Effects
163
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
163


